Abstract

Benign prostatic hyperplasia (BPH) — one of the most common urological diseases that lead to the development of symptoms of the lower urinary tract (SLUT). BPH-multifactorial disease, in which a significant role is given to increase the activity of the enzyme 5a-reductase and hormonal imbalance associated with the exchange of testosterone and dihydrotestosterone. However, to date, not all aspects of the etiology and pathogenesis of this condition have been studied. The results of numerous studies indicate a significant role of complex metabolic disorders included in the modern concept of "metabolic syndrome" (MS), the development and progression of BPH/SLUT. The main pathogenetic factors leading to the formation of BPH and concomitant urination disorders are considered to be a violation of the balance of sex hormones, the development of chronic ischemia of the pelvic organs, a violation of carbohydrate and lipid metabolism. The relationship between BPH and MS is one of the most urgent problems of modern medicine. Different components of MS independently from each other can influence more pronounced progression of BPH/SLUT in comparison with development of this disease in men without metabolic disorders that is the reason of lower efficiency of surgical and medical treatment of this group of patients.

Highlights

  • Research’n Practical Medicine Journal 2018, v.5, No4, p. 46-57 V.B.Filimonov, R.V.Vasin et al / The influence of metabolic syndrome on the development and clinical manifestations of benign prostatic hyperplasia

  • Does metabolic syndrome or its components correlate with lower urinary tract symptoms in benign prostatic hyperplasia patients? Nephrourol Mon. 2015 May 23;7 (3 ):e27253

  • The relationships between metabolic syndrome, erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia

Read more

Summary

Introduction

Research’n Practical Medicine Journal 2018, v.5, No4, p. 46-57 V.B.Filimonov, R.V.Vasin et al / The influence of metabolic syndrome on the development and clinical manifestations of benign prostatic hyperplasia. При этом у больных с ДГПЖ и сопутствующим МС зарегистрировано значительное увеличение общего объема предстательной железы (на 7,37– 12,93 мл) и более высокий уровень простатспецифического антигена (ПСА) общей плазмы крови (на 0,17–0,88 нг/мл) по сравнению с пациентами без МС. У пациентов с МС отмечался достоверно (95%) больший объем предстательной железы (32,6 по сравнению с 23,9 см3) и концентрации ПСА плазмы крови (1,16 нг/мл по сравнению с 0,50 нг/мл), а также более выраженные СНМП, оцененные по шкале IPSS (число баллов от 20 до 35, среднее значение — 27,5) было у 14,5% исследуемых по сравнению с 0,6% в группе контроля.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.